Table 1

Summary of patient characteristics

Patient characteristicsRandomized and treated patients
Fully supplemented patients
Pemetrexed + cisplatin (n = 226)Cisplatin (n = 222)Pemetrexed + cisplatin (n = 168)Cisplatin (n = 163)
Age (y)
    Median (range)61 (29-85)60 (19-84)60 (29-85)60 (19-82)
Gender (%)
    Male184 (81.4)181 (81.5)136 (81.0)134 (82.2)
    Female42 (18.6)41 (18.5)32 (19.0)29 (17.8)
Origin (%)
    Caucasian204 (90.3)206 (92.8)150 (89.3)153 (93.9)
    Hispanic11 (4.9)12 (5.4)10 (6.0)7 (4.3)
    Asian10 (4.4)4 (1.9)7 (4.2)3 (1.8)
    African descent1 (0.4)01 (0.6)0
Stage at entry (%)
    I16 (7.1)14 (6.3)15 (8.9)12 (7.4)
    II35 (15.6)33 (15.0)27 (16.2)27 (16.8)
    III73 (32.4)68 (30.6)51 (30.5)49 (30.4)
    IV101 (44.9)105 (47.2)74 (44.3)73 (45.3)
    Unspecified1 (0.4)2 (0.9)1 (0.6)2 (1.2)
Diagnosis/histology* (%)
    Epithelial154 (68.1)152 (68.5)117 (69.6)113 (69.3)
    Mixed37 (16.4)36 (16.2)25 (14.9)25 (15.3)
    Sarcomatoid18 (8.0)25 (11.3)14 (8.3)17 (10.4)
    Other17 (7.5)9 (4.1)12 (7.1)8 (4.9)
Baseline Karnofsky Performance Scale (%)
    70-80109 (48.2)97 (43.7)83 (49.4)69 (42.3)
    90-100117 (51.8)125 (56.3)85 (50.6)94 (57.7)
  • * Only 67% of the patients had the histologic diagnosis of malignant mesothelioma confirmed by independent review. After independent review epithelial, mixed, and sarcomatoid were the only subtypes; there were no “other.”